Innovative Cannabis-Derived Epilepsy Treatment Reaches UK Patients
A leading European pharmaceutical firm specializing in plant-derived medications, MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF) has successfully imported and delivered its ground-breaking Investigational Medicinal Product (IMP), CannEpil, to its first patients in the United Kingdom.
